REGN · Full Picture

REGENERON PHARMACEUTICALS, INC. — the full picture

Trailing window · 2026-05-12 to 2026-08-10

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Securities Fraud Litigation · Litigation & settlementsPriority 38
    1 forward row(s); quote_verified
    A securities class action lawsuit has been filed on behalf of Regeneron investors after its stock plummeted almost 10% because Regeneron allegedly misled investors regarding the success of its Phase III Fianlimab-Libtayo clinical trial.
  2. Competition and Market Share · Competition & market sharePriority 37
    quote_verified
    Analysts and reports note new biosimilar competition for Eylea as a challenge for Regeneron.
  3. Product / Drug Pipeline Progress · Products & launchesPriority 35
    quote_verified
    The Faruqi notice alleges Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, which ultimately failed to reach statistical significance.
  4. Revenue Performance and Mix · Revenue growth & mixPriority 30
    quote_verified
    Regeneron reported Q2 2026 EPS of $14.29 and revenue of $4.29 billion, beating analyst expectations.
  5. Capital Return Program · Buybacks & dividendsPriority 28
    quote_verified
    Regeneron confirmed a quarterly dividend and updated on share repurchases in connection with its Q2 and H1 2026 results.

Threads by pillar

Revenue & Demand Priority 38 · 2 threads

Capital & Balance Sheet Priority 28 · 1 thread

Legal, Regulatory & Policy Priority 38 · 1 thread

Macro & Market Conditions Priority 37 · 1 thread